99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Recruiting now · Phase 2/Phase 3

Conditions studied: Parathyroid Adenoma

In brief

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Key facts

Study ID

NCT05891769

Run by

Andrei Iagaru

People needed

100

Starts

2023-09-27

Expected to finish

2028-07-01

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or high levels of parathyroid hormone)
• Negative or equivocal 99mTc Sestamibi SPECT/CT
• Able to provide written consent
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 xULN
• Karnofsky performance status of >50 (or ECOG/WHO equivalent)
• Women must not be pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women.

You may not qualify if…

• Less than 18 years old at the time of radiotracer administration
• Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x ULN
• QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome

Where it is running

• Stanford Hospital and Clinics — Stanford, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.